Wellysis Secures FDA 510(k) Clearance for S-Patch CardioAI

Wellysis has secured FDA 510(k) clearance for S-Patch CardioAI, according to PR Newswire. The announcement identifies S-Patch CardioAI as AI-powered electrocardiogram analysis software.

PR Newswire describes Wellysis as a digital health company specializing in wearable ECG monitoring. The reported clearance places the company’s ECG analysis software within its stated wearable-monitoring focus.

FDA clearance announcement

According to PR Newswire, Wellysis announced FDA 510(k) clearance for S-Patch CardioAI. The publisher’s headline describes the product as AI-powered ECG analysis software.

The announcement provides a regulatory milestone for Wellysis and its named software product. Wellysis’s stated specialty in wearable electrocardiogram monitoring provides the technology context included in the report.

For medical sales professionals, the announcement offers a defined update to track in discussions involving ECG analysis software, wearable ECG monitoring, and digital health technology. PR Newswire attributes the clearance announcement to Wellysis.

What the announcement identifies

• Company: Wellysis.
• Regulatory event: FDA 510(k) clearance.
• Product: S-Patch CardioAI.
• Product description: AI-powered ECG analysis software.
• Company focus: Wearable ECG monitoring.

The PR Newswire report centers on the clearance and the product’s stated ECG analysis role. It also identifies Wellysis as operating in digital health, with a specialization in wearable ECG monitoring.

When reviewing the news, sales professionals can separate the reported regulatory event from the product and company descriptions included in the announcement. The available report identifies the FDA 510(k) clearance, S-Patch CardioAI, AI-powered ECG analysis software, and Wellysis’s wearable ECG monitoring specialization.

Industry context

The clearance announcement adds a new reported FDA 510(k) event to the wearable ECG monitoring and ECG analysis software landscape. PR Newswire’s coverage names Wellysis and S-Patch CardioAI as the company and product associated with the announcement.

Additional product claims, intended use, and clinical details are not included in the supplied report. The reported facts are limited to the FDA 510(k) clearance announcement and the company’s and product’s stated descriptions.